LEXICON PHARMACEUTICALS, INC. (LXRX) — SEC Financial Statements & Analysis

LEXICON PHARMACEUTICALS, INC. (LXRX) is a pharmaceutical preparations company, incorporated in DE. LEXICON PHARMACEUTICALS, INC. trades on Nasdaq as: LXRX. LEXICON PHARMACEUTICALS, INC. (LXRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, LEXICON PHARMACEUTICALS, INC. carries a market cap of $1.05B, a P/E ratio of -17.19x, a P/B ratio of 6.02x, a P/S ratio of 25.33x, an enterprise value of $1.06B, and an EV/EBITDA multiple of -19.64x. On profitability, it posts a gross margin of 99.14%, an operating margin of -131.43%, a net margin of -147.38%, a Return on Equity (ROE) of -40.21%, a Return on Assets (ROA) of -25.70%, and a Return on Invested Capital (ROIC) of -33.83%. Per share, it reports EPS of $-0.14, diluted EPS of $-0.14, free cash flow per share of $-0.15, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -29.11% year-over-year, net income growth of -49.33% year-over-year, and EPS growth of -57.94% year-over-year. On the balance sheet, it maintains a current ratio of 13.37x, a quick ratio of 13.29x, working capital of $181.87M, a debt-to-equity ratio of 0.43x, a debt ratio of 0.3, an interest coverage ratio of -50.54x, free cash flow of $-64.99M (TTM), and net debt of $10.51M. Figures sourced from SEC EDGAR.

Market Cap

$1.05B

P/E TTM

-17.19x

EPS TTM

$-0.14

P/B TTM

6.02x

ROE TTM

-40.21%

ROA TTM

-25.70%

Debt To Equity

0.43x

Free Cash Flow TTM

$-64.99M

Net Revenue TTM Growth 1Y

-29.11%

Data as of 2026-06-30 · Source: SEC EDGAR